sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose-escalation study of sEphB4-HSA in combination with chemotherapy,
cetuximab and radiotherapy (RT). The purpose is to estimate the maximum tolerated dose (MTD)
that can be administered concurrently with Cetuximab and radiation in patients with locally
advanced, Stage III or IV A-B squamous cell carcinomas of the head or neck with a history of
at least ten pack-years of smoking.
Phase:
Phase 1
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
National Cancer Institute (NCI) Vasgene Therapeutics, Inc